1. Mesenchymal stromal cell treatment of donor kidneys during ex vivo normothermic machine perfusion
- Author
-
Bente Jespersen, Stina J M Lignell, Søren Krag, Marco Eijken, Maria Letizia Lo Faro, Jesus Maria Sierra-Parraga, Henri G. D. Leuvenink, Stine Lohmann, Carla C. Baan, Anna Krarup Keller, James P. Hunter, Cyril Moers, Rutger J. Ploeg, Merel B F Pool, Kaithlyn M Rozenberg, Martin J. Hoogduijn, Bjarne Kuno Møller, Ulla Møldrup, Groningen Institute for Organ Transplantation (GIOT), and Internal Medicine
- Subjects
basic (laboratory) research/science ,medicine.medical_specialty ,Swine ,medicine.medical_treatment ,Urology ,organ procurement and allocation ,regenerative medicine ,kidney transplantation/nephrology ,030230 surgery ,Kidney ,Transplantation, Autologous ,03 medical and health sciences ,0302 clinical medicine ,stem cells ,Immunology and Allergy ,Medicine ,Animals ,Humans ,Pharmacology (medical) ,Transplantation ,Machine perfusion ,business.industry ,organ perfusion and preservation ,Mesenchymal stem cell ,Mesenchymal Stem Cells ,Organ Preservation ,donation after circulatory death (DCD) [donors and donation] ,Autotransplantation ,Nephrectomy ,Perfusion ,ischemia reperfusion injury (IRI) ,medicine.anatomical_structure ,business ,Ex vivo - Abstract
Normothermic machine perfusion (NMP) of injured kidneys offers the opportunity for interventions to metabolically active organs prior to transplantation. Mesenchymal stromal cells (MSCs) can exert regenerative and anti-inflammatory effects in ischemia-reperfusion injury. The aims of this study were to evaluate the safety and feasibility of MSC treatment of kidneys during NMP using a porcine autotransplantation model, and examine potential MSC treatment-associated kidney improvements up to 14 days posttransplant. After 75 min of kidney warm ischemia, four experimental groups of n = 7 underwent 14 h of oxygenated hypothermic machine perfusion. In three groups this was followed by 240 min of NMP with infusion of vehicle, 10 million porcine, or 10 million human adipose-derived MSCs. All kidneys were autotransplanted after contralateral nephrectomy. MSC treatment did not affect perfusion hemodynamics during NMP or cause adverse effects at reperfusion, with 100% animal survival. MSCs did not affect plasma creatinine, glomerular filtration rate, neutrophil gelatinase-associated lipocalin concentrations or kidney damage assessed by histology during the 14 days, and MSCs retention was demonstrated in renal cortex. Infusing MSCs during ex vivo NMP of porcine kidneys was safe and feasible. Within the short posttransplant follow-up period, no beneficial effects of ex vivo MSC therapy could be demonstrated.
- Published
- 2021